logo

For the Inventor, By the Inventor

Jerusalem, Israel

David Lerner

This inventor holds 17 USPTO granted patents, primarily in Pharmaceutical Formulations. Top assignees: Teva Pharmaceutical Industries Limited, Technion Research & Development Foundation Ltd, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 1995-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Lerner. Retrieved from https://idiyas.com/inventor/david-lerner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17

% Patents Active = 76.5

Average Co-Inventor Count = 6.8

ph-index = 14

Forward Citations = 526(Granted Patents)


Company Filing History:

goldMedal14 out of 505 
 
Teva Pharmaceutical Industries Limited
 patents
silverMedal10 out of 1,005 
 
Technion Research & Development Foundation Ltd
 patents
bronzeMedal3 out of 916 
 
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
 patents
4. 1 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 1995-2013

Loading Chart...
Areas of Expertise:
Rasagiline
Propargylated Aminoindans
Anti-Inflammatory
Immunomodulatory Agents
Pharmaceutical Compositions
Valproic Acid Derivatives
R-Enantiomer
Polyamine Derivatives
Aminoindans
Salts
Compositions
Processes
17 patents (USPTO):Explore Patents
1. 8609719 - Propargylated aminoindans, processes for preparation, and uses thereof (2013-12-17),
2. 7625946 - Propargylated aminoindans, processes for preparation, and uses thereof (2009-12-01),
3. 7598420 - Rasagiline formulations and processes for their preparation (2009-10-06),
4. 7572834 - Rasagiline formulations and processes for their preparation (2009-08-11),
5. 7294739 - Basic amine esters or oleic acid and their use as anti-inflammatory or immunobodulatory agents (2007-11-13),
6. 6956060 - Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof (2005-10-18),
7. 6316504 - Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof (2001-11-13),
8. 5786390 - Pharmaceutical compositions of the R-enantiomer of N-propargyl (1998-07-28),
9. 5744500 - Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions (1998-04-28),
10. 5668181 - Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for the (1997-09-16),
11. 5646188 - Polyamine derivatives of 1-aminoindan (1997-07-08),
12. 5599991 - Esylate and sulfate salts of R(+)-N-propargyl-1-aminoindan (1997-02-04),
13. 5585358 - Derivatives of valproic acid amides and 2-valproenoic acid amides, (1996-12-17),
14. 5532415 - R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses (1996-07-02),
15. 5457133 - R-enantiomers of N-propargyl-aminoindan compounds, their preparation and (1995-10-10),

Title: Innovations by David Lerner in Pharmaceutical Development

Introduction

David Lerner, an esteemed inventor based in Jerusalem, IL, has made significant contributions to the field of pharmaceuticals with a total of 17 patents to his name. His work primarily focuses on the development of innovative compounds for therapeutic uses, particularly in the treatment of Alzheimer's disease.

Latest Patents

Among his latest innovations, Lerner has created a groundbreaking method for treating individuals identified as having Alzheimer’s disease. This involves administering a therapeutically effective amount of ladostigil or its pharmaceutically active salts orally. The recommended doses range from 70 mg per day to 200 mg per day. Additionally, he has developed unit dosage forms of ladostigil in amounts of 50 mg, 70 mg, 80 mg, or 100 mg. This collection of patents around propargylated aminoindans illustrates his commitment to advancing healthcare solutions.

Career Highlights

David Lerner's career has seen him collaborating with prominent companies such as Teva Pharmaceutical Industries Limited and the Technion Research & Development Foundation Limited. These affiliations underscore his active engagement in pharmaceutical innovation and research.

Collaborations

Throughout his career, Lerner has worked alongside notable colleagues, including Jeffrey Sterling and Ruth Levy. Their collaborations likely provided a platform for sharing ideas and accelerating the development of important pharmaceutical technologies.

Conclusion

David Lerner continues to be a pivotal figure in the realm of pharmaceutical inventions. His innovative work, particularly concerning the treatment of Alzheimer's disease, reflects a profound dedication to improving patient outcomes through scientific advancements. As the healthcare landscape evolves, his contributions will likely play a crucial role in shaping future therapeutic strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…